세계의 메틸말론산혈증(MMA) 시장 보고서(2025년)

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder in which the body is unable to effectively break down certain proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The severity of MMA symptoms can vary, but they often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.

The primary indications for methylmalonic acidemia (MMA) include acidosis, ketosis, hyperammonemia, hypoglycemia, hyperglycemia, neutropenia, and other related conditions. Acidosis refers to an excess of acid in the blood, resulting in a lower-than-normal pH level. There are various types of disorders associated with MMA, such as homocystinuria, isolated methylmalonic acidurias, and combined methylmalonic aciduria. These treatments and interventions are available through different distribution channels, including hospitals, pharmacies, clinics, and other outlets.

The methylmalonic acidemia (MMA) market research report is one of a series of new reports from The Business Research Company that provides methylmalonic acidemia (MMA) market statistics, including the methylmalonic acidemia (MMA) industry global market size, regional shares, competitors with the methylmalonic acidemia (MMA) market share, detailed methylmalonic acidemia (MMA) market segments, market trends, and opportunities, and any further data you may need to thrive in the methylmalonic acidemia (MMA) industry. This methylmalonic acidemia (MMA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The methylmalonic acidemia (MMA) market size has grown strongly in recent years. It will grow from $9.39 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to factors such as the rising incidence of metabolic disorders and vitamin deficiencies, increased healthcare spending, greater health consciousness, a higher prevalence of genetic disorders, and growing demand from various end-user industries.

The methylmalonic acidemia (MMA) market size is expected to see strong growth in the next few years. It will grow to $12.50 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth projected for the forecast period is driven by factors such as the expansion of newborn screening programs, increased awareness among healthcare professionals, advancements in gene therapy, growing investments in rare disease research, and improved availability of specialized treatments. Key trends expected during this period include advancements in gene editing technologies, enhanced diagnostic techniques for early detection, progress in enzyme replacement therapies, the adoption of precision medicine approaches, and the growing implementation of newborn genetic screening programs.

The rising prevalence of metabolic disorders and vitamin deficiencies is expected to drive the growth of the methylmalonic acidemia (MMA) market. Metabolic disorders are conditions where the body struggles to process certain nutrients, produce energy, or regulate chemical reactions within cells. Vitamin deficiencies occur when the body lacks enough specific vitamins to function properly. The increase in metabolic disorders and vitamin deficiencies is largely attributed to poor diets, sedentary lifestyles, and heightened stress levels. Modern diets, which are often rich in processed foods, sugars, and unhealthy fats while lacking essential nutrients, contribute to deficiencies in vitamins and minerals. These metabolic disorders and vitamin deficiencies, especially vitamin B12 deficiency, disrupt methylmalonyl-CoA metabolism, leading to the buildup of methylmalonic acid and worsening MMA. For example, in November 2024, the National Institutes of Health reported that the prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, adding 507 cases between the third and fourth quarters of 2023. As a result, the growing incidence of metabolic disorders and vitamin deficiencies is fueling the expansion of the MMA market.

Leading companies in the MMA market are focusing on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes by targeting the genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies use messenger RNA to instruct cells to produce specific proteins that help treat diseases, including genetic disorders. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received FDA approval to include mRNA-3705 in the START pilot program, a significant advancement for rare disease treatments. mRNA-3705 is an investigational therapy for MMA caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy uses Moderna's proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, expediting its development and clinical progress.

In October 2022, Alexion Pharmaceuticals, a US-based biopharmaceutical company, acquired LogicBio Therapeutics for approximately $68.2 million. This acquisition aims to accelerate Alexion's growth in genomic medicines by utilizing unique technology, a talented rare disease research team, and expertise in preclinical development. LogicBio Therapeutics, Inc. is a US-based biotechnology company specializing in gene-editing and gene therapy solutions for rare genetic diseases, including MMA.

Major players in the methylmalonic acidemia (mma) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in methylmalonic acidemia (MMA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the methylmalonic acidemia (MMA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The methylmalonic acidemia (MMA) market consists of revenues earned by entities by providing services such as medical management, dietary support, and vitamin and medication therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The methylmalonic acidemia market includes sales of hydroxocobalamin, vitamin B12 tablets, other pharmaceutical and therapeutic products, dietary products, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Methylmalonic Acidemia (MMA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on methylmalonic acidemia (mma) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for methylmalonic acidemia (mma) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The methylmalonic acidemia (mma) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications
• 2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria
• 3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels
• Subsegments:
• 1) By Acidosis: Metabolic Acidosis; Lactic Acidosis
• 2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis
• 3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia
• 4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi
• 5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia
• 6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia
• 7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction
• Companies Mentioned: Moderna Inc.; Lonza Group Ltd.; Alexion Pharmaceuticals Inc.; PTC Therapeutics Inc.; Ironwood Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Methylmalonic Acidemia (MMA) Market Characteristics

3. Methylmalonic Acidemia (MMA) Market Trends And Strategies

4. Methylmalonic Acidemia (MMA) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Methylmalonic Acidemia (MMA) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Methylmalonic Acidemia (MMA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Methylmalonic Acidemia (MMA) Market Growth Rate Analysis
• 5.4. Global Methylmalonic Acidemia (MMA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Methylmalonic Acidemia (MMA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Methylmalonic Acidemia (MMA) Total Addressable Market (TAM)

6. Methylmalonic Acidemia (MMA) Market Segmentation

• 6.1. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acidosis
• Ketosis
• Hyperammonemia
• Hypoglycaemia
• Hyperglycaemia
• Neutropenia
• Other Indications
• 6.2. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Homocystinuria
• Isolated Methylmalonic Acidurias
• Combined methylmalonic Aciduria
• 6.3. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmacies
• Clinics
• Other Distribution Channels
• 6.4. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Acidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metabolic Acidosis
• Lactic Acidosis
• 6.5. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Ketosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Starvation-Induced Ketosis
• Diabetic Ketoacidosis
• 6.6. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Hyperammonemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hyperammonemia
• Chronic Hyperammonemia
• 6.7. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Hypoglycemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fasting Hypoglycemia
• Reactive Hypoglycemi
• 6.8. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Neutropenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe Neutropenia
• Cyclic Neutropenia
• 6.9. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Failure to Thrive
• Developmental Delays
• Neurological Symptoms
• Renal Dysfunction

7. Methylmalonic Acidemia (MMA) Market Regional And Country Analysis

• 7.1. Global Methylmalonic Acidemia (MMA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Methylmalonic Acidemia (MMA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Methylmalonic Acidemia (MMA) Market

• 8.1. Asia-Pacific Methylmalonic Acidemia (MMA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Methylmalonic Acidemia (MMA) Market

• 9.1. China Methylmalonic Acidemia (MMA) Market Overview
• 9.2. China Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Methylmalonic Acidemia (MMA) Market

• 10.1. India Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Methylmalonic Acidemia (MMA) Market

• 11.1. Japan Methylmalonic Acidemia (MMA) Market Overview
• 11.2. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Methylmalonic Acidemia (MMA) Market

• 12.1. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Methylmalonic Acidemia (MMA) Market

• 13.1. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Methylmalonic Acidemia (MMA) Market

• 14.1. South Korea Methylmalonic Acidemia (MMA) Market Overview
• 14.2. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Methylmalonic Acidemia (MMA) Market

• 15.1. Western Europe Methylmalonic Acidemia (MMA) Market Overview
• 15.2. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Methylmalonic Acidemia (MMA) Market

• 16.1. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Methylmalonic Acidemia (MMA) Market

• 17.1. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Methylmalonic Acidemia (MMA) Market

• 18.1. France Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Methylmalonic Acidemia (MMA) Market

• 19.1. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Methylmalonic Acidemia (MMA) Market

• 20.1. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Methylmalonic Acidemia (MMA) Market

• 21.1. Eastern Europe Methylmalonic Acidemia (MMA) Market Overview
• 21.2. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Methylmalonic Acidemia (MMA) Market

• 22.1. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Methylmalonic Acidemia (MMA) Market

• 23.1. North America Methylmalonic Acidemia (MMA) Market Overview
• 23.2. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Methylmalonic Acidemia (MMA) Market

• 24.1. USA Methylmalonic Acidemia (MMA) Market Overview
• 24.2. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Methylmalonic Acidemia (MMA) Market

• 25.1. Canada Methylmalonic Acidemia (MMA) Market Overview
• 25.2. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Methylmalonic Acidemia (MMA) Market

• 26.1. South America Methylmalonic Acidemia (MMA) Market Overview
• 26.2. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Methylmalonic Acidemia (MMA) Market

• 27.1. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Methylmalonic Acidemia (MMA) Market

• 28.1. Middle East Methylmalonic Acidemia (MMA) Market Overview
• 28.2. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Methylmalonic Acidemia (MMA) Market

• 29.1. Africa Methylmalonic Acidemia (MMA) Market Overview
• 29.2. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Methylmalonic Acidemia (MMA) Market Competitive Landscape And Company Profiles

• 30.1. Methylmalonic Acidemia (MMA) Market Competitive Landscape
• 30.2. Methylmalonic Acidemia (MMA) Market Company Profiles
  • 30.2.1. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Alexion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ironwood Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Methylmalonic Acidemia (MMA) Market Other Major And Innovative Companies

• 31.1. Wockhardt Limited
• 31.2. Spectrum Chemical Manufacturing Corp.
• 31.3. Asklepios BioPharmaceutical Inc. (AskBio)
• 31.4. Selecta Biosciences Inc.
• 31.5. BTG International Inc.
• 31.6. BridgeBio Pharma Inc.
• 31.7. VectivBio Holding AG
• 31.8. Supriya Lifescience Ltd.
• 31.9. Recordati Rare Diseases Inc.
• 31.10. Agios Pharmaceuticals Inc.
• 31.11. AdvaCare Pharma USA LLC
• 31.12. LogicBio Therapeutics Inc.
• 31.13. HemoShear Therapeutics LLC
• 31.14. Manus Aktteva Biopharma LLP
• 31.15. Deccan Nutraceuticals Pvt. Ltd.

32. Global Methylmalonic Acidemia (MMA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Methylmalonic Acidemia (MMA) Market

34. Recent Developments In The Methylmalonic Acidemia (MMA) Market

35. Methylmalonic Acidemia (MMA) Market High Potential Countries, Segments and Strategies

• 35.1 Methylmalonic Acidemia (MMA) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Methylmalonic Acidemia (MMA) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Methylmalonic Acidemia (MMA) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer